We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Maternal HbA1c Influences Autism Risk in Offspring

By LabMedica International staff writers
Posted on 04 Jul 2019
Print article
Image: An increase in HBA1c levels in pregnancy is associated with an increased risk for autism in the child (Photo courtesy of Thai Anti-Diabetes).
Image: An increase in HBA1c levels in pregnancy is associated with an increased risk for autism in the child (Photo courtesy of Thai Anti-Diabetes).
Epidemiologic data suggest that maternal diabetes influences the risk for autism in offspring, whereas the prevalence of autism has steadily risen in the USA, currently affecting 1 in 59 children, and boys are four to five times more likely to receive an autism diagnosis.

According to a comprehensive survey children born to women with glycated hemoglobin (HbA1c) level of at least 6.5% were nearly twice as likely to receive a diagnosis of autism in the first four years of life versus offspring of mothers with HbA1c below 5.7%.

Scientists carried out a retrospective study and analyzed electronic medical records data from 35,819 mother-infant pairs (51% boys) born in hospitals connected to Kaiser Permanente Southern California (Pasadena, CA, USA) from 2012 to 2013 (maternal mean maternal age, 31 years; mean pre-pregnancy BMI, 27.2 kg/m²; 51% Hispanic). The team followed the children until they received a diagnosis of autism with at least one diagnostic code or December 31, 2017. The last maternal HbA1c level in the first two trimesters of pregnancy was obtained from the electronic laboratory database. HbA1c was analyzed as a continuous variable and a categorical variable, classified as less than 5.7%, 5.7% to 5.9%, 6% to 6.5%, and greater than 6.5%.

Within the cohort, 84.9% of mothers had an HbA1c less than 5.7%; 11.7% had an HbA1c between 5.7% and 5.9; 2.4% between 6% and 6.5%; and 1% greater than 6.5%. During a median follow-up of 4.5 years, 707 children (2%) had a clinical diagnosis of autism. After adjusting for pre-pregnancy BMI and race, the Hazard Ratio (HR) for autism associated with each 1% increase of HbA1c level was 1.12 (95% CI, 0.96-1.31) for the continuous measure. Compared with children with a maternal HbA1c of less than 5.7%, children born to women with an HbA1c greater than 6.5% were nearly twice as likely to receive a diagnosis of autism during follow-up (HR = 1.79; 95% CI, 1.06-3).

Anny H. Xiang, PhD, director of biostatistics for Kaiser Permanente Southern California, said, “Maternal diabetes, if not well treated, which means hyperglycemia in utero, that increases uterine inflammation, oxidative stress and hypoxia and may alter gene expression. This can disrupt fetal brain development, increasing the risk for neural behavior disorders, such as autism.” The study was presented at the American Diabetes Association 79th Scientific Meeting held June 7-11, 2019, in San Francisco, CA, USA.

Related Links:
Kaiser Permanente Southern California

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.